Background
The prevention of infection is an important goal influencing perioperative care of extremity fracture patients. Standard practice in the operative management of extremity fractures includes sterile technique and pre-operative skin preparation with an antiseptic solution. The available solutions kill bacteria and decrease the quantity of native skin flora, thereby decreasing surgical site infection (SSI). While there is extensive guidance on specific procedures for prophylactic antibiotic use and standards for sterile technique, the evidence regarding the choice of antiseptic skin preparation solution is very limited for extremity fracture surgery.
Objectives
The overarching objective of this trial is to compare the effectiveness of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol versus 2% chlorhexidine gluconate (CHG) in 70% isopropyl alcohol for the management of extremity fractures that require surgical treatment. The primary outcome for comparison is surgical site infection (SSI) , and the secondary outcome is unplanned fracture-related reoperation.
Open and Closed Fractures Populations
Open fracture patients and closed fracture patients represent two distinct populations within extremity fracture surgery. Open and closed fracture participants will be recruited separately to independently compare the effectiveness of the study solutions in each population. Therefore, our effectiveness comparisons will be performed separately within the open fracture and closed fracture populations.
Subgroup Objectives
The PREPARE trial will also explore the possibility of differential treatment effects of the pre-operative antiseptic skin solutions among clinically important subgroups. The open fracture subgroups will be defined by i) the severity of open fracture (Gustilo-Anderson type I or II versus III); 1 ii) upper extremity versus lower extremity open fractures; iii) severity of wound contamination; and, iv) presence or absence of comorbidities that affect wound healing. The closed fracture subgroups will be defined by: i) severity of soft Version: 2.1 04-Nov-2019 tissue injury (higher Tscherne injuries) and ii) presence or absence of comorbidities that affect wound healing.
Diagnosis and Main Inclusion Criteria
All patients 18 years of age or older who present to a recruiting hospital for treatment of an open fracture(s) of the appendicular skeleton will be screened for participation within 3 weeks of their fracture. All patients 18 years of age or older who present to a recruiting hospital for surgical treatment of a closed lower extremity or pelvic fracture(s) will be screened for participation within 6 weeks of their fracture. Eligible patients must have an open fracture of the appendicular skeleton or have a closed lower extremity or pelvic fracture, and their fractures must be definitively managed with a surgical implant (e.g., internal fixation, external fixation (open fractures and in closed fractures that require a surgical incision), joint prosthesis, etc.).
Treatment Groups
The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ [3M Health Care, St Paul, MN], will be the commercial product used. The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® [CareFusion Inc., Leawood, KS, USA] will be the commercial product used.
Randomization
Treatment allocation will be determined using a cluster-randomized crossover trial design. The open and closed fracture populations will be treated with the same allocated solution at all times during the trial. The order of treatment allocation for each orthopaedic practice will be randomly assigned using a computer-generated randomization table. Each site will start with the initially allocated study solution and eventually crossover to the other solution for their second recruitment period. This process of alternating treatments will repeat approximately every 2 months as dictated by the initial randomization.
Study Outcomes
The primary outcome is SSI, guided by the Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network reporting criteria, which includes superficial incisional SSI within 30 days and deep incisional or organ/space SSI within 90 days of definitive fracture management surgery. The secondary outcome is the occurrence of an unplanned fracture-related reoperation within 12 months of the fracture. Alternative definitions of SSI, including the confirmatory criteria for FractureRelated Infection (FRI) and the CDC criteria within 1 year of injury will be used for sensitivity analyses of the primary comparison. All study outcomes will be adjudicated by a blinded committee using clinical notes and radiographs. Version: 2.1 04-Nov-2019 124 125
Follow-Up
Study participants will be followed at 6 weeks, 3 months, 6 months, 9 months, and 12 months from their fracture.
Sample Size
A minimum of 1,540 participants with open fractures and a minimum of 6,280 participants with closed lower extremity or pelvic fractures will be included in PREPARE.
Significance
SSIs are often devastating complications for fracture patients because of the resultant reoperations, adverse events from antibiotic courses, and fracture healing difficulties. Given the substantial impact of extremity fractures, maximizing the effectiveness of current prophylactic procedures is essential. The PREPARE trial will provide necessary evidence to guide the prevention of SSIs in fracture care, and the trial is poised to have a significant impact on the care and outcomes of extremity fracture patients.
INTRODUCTION
126 127
Extremity Fractures and Surgical Site Infections 128
More than one million Americans suffer an extremity fracture (broken bone in the arm, leg, or 129 pelvis) that requires surgery each year. 2, 3 Approximately 5% (or 50,000) of surgical fracture 130 patients develop a surgical site infection (SSI), 4,5 which is twice the rate among most surgical 131 patients and nearly five times the rate among patients undergoing elective orthopaedic surgeries 132 (e.g., joint replacement). 6 Patients who develop a SSI after their fracture fixation surgery 133
experience a long and difficult treatment pathway. Researchers have identified that when a 134 fracture patient experiences a SSI, they typically undergo at least two additional surgeries to 135 control the infection, spend a median of 14 additional days in the hospital, and have significantly 136
lower health related quality of life (HRQL). 7 Similarly, results from the recently completed Fluid problem (n= 188/323). This is consistent with the data presented in Figure 1 , confirming a high 300 proportion of fracture infections requiring surgery occurred beyond the 90-day surveillance 301 period for SSI. 18 Therefore, given the rationale that iodophors may be more effective in 302 preventing SSI, it is clinically plausible that its use may also reduce unplanned fracture-related 303 reoperations. 304 305
Lack of Surgeon Consensus 306
The FLOW trial demonstrated a clear divide among orthopaedic surgeons regarding their choice 307 to use the two most common antiseptic solutions during open fracture fixation surgery. 4 Iodophor 308 solutions were used in 54% of the surgeries performed, while 41% were performed using CHG 309
solutions. The remaining surgeons either used both iodophor and CHG (4%), or alcohol with no 310 iodophor or CHG (1%). 4 Building upon the lack of consensus among orthopaedic surgeons 311 participating in the FLOW trial, our research team conducted an internet-based survey (n = 210) 312
and several interviews with orthopaedic surgeons to understand the reasons for the lack of 313 consensus in the use of surgical preparation solutions. Similar to the observations of the FLOW 314 trial, there was nearly an equal split between the use of iodophor and CHG solutions in open and 315 closed fracture surgery. More insight was gained in interviews with the surgeons. Three main 316 drivers for surgeon decision-making were identified: 1) they continued to use the antiseptic 317 solution shown to them during their surgical training, 2) they used the solution recommended by 318 their hospital, or 3) they felt the tissue toxicity was less with their chosen solution. No surgeon 319 could cite a clinical study that helped guide their decision, despite all surgeons indicating they 320 believed the antiseptic solution was important for reducing their patient's risk of SSI. Limited 321 consensus among surgeons reflects a lack of compelling evidence on the optimal approaches to 322 surgical skin preparation, further vindicating the need for a large definitive trial. 323 324
The PREPARE Trial, A Pragmatic Randomized trial Evaluating Pre-operative Alcohol skin 325 solutions in FRactured Extremities, will address these gaps in the literature. 326 327 2.0 STUDY OBJECTIVES AND HYPOTHESES 328 329
Study Objectives and Hypotheses 330
The overarching objective of this trial is to compare the effectiveness of iodine povacrylex (0.7% 331 free iodine) in 74% isopropyl alcohol versus 2% CHG in 70% isopropyl alcohol for the 332 management of extremity fractures that require surgical treatment. Open and closed fracture 333 participants will be recruited separately to compare the independent effectiveness of the study 334 solutions in each population. SSI will be the primary outcome for comparing effectiveness 335 (primary objective), and unplanned fracture-related reoperation will be the secondary outcome 336 for comparison (secondary objective The closed fracture subgroups will be defined by: i) severity of soft tissue injury (Tscherne grade 371 3 versus grades 0-2), and ii) presence or absence of comorbidities that affect wound healing. 372 373
Subgroup Hypotheses 374
It has been established that several patient and injury factors are frequently associated with worse 375 patient outcomes after extremity fractures. 30, 31 As a result, we hypothesize that iodine povacrylex 376 (0.7% free iodine) in 74% isopropyl alcohol will be associated with a larger reduction in odds for 377 SSI and unplanned fracture-related reoperations among patients with a higher risk for extremity 378 fracture SSI. Specifically, in both the open and closed fracture populations we expect to observe 379 this heterogeneity of treatment effect in patients with more severe soft tissue injury and patients 380 with increased comorbidities due to the potentially broader antimicrobial coverage, stronger 381 tissue adherence, and increased antiseptic longevity of iodine povacrylex. 32 The credibility of all 382 subgroup analyses will be assessed in accordance with criteria outlined by Sun et al. fracture patients in total) as applicable, and that most clinical sites will exceed this minimum 421 recruitment goal. Clinical site personnel will screen potential patients for eligibility, and if 422 eligible, they will be invited to participate in the trial. Study participants will be assessed at 423 regular intervals in the one year following their fracture. The primary outcome will include any 424 SSI event from the time of fracture to the end of the 30-and 90-day post-operative periods from 425 their definitive fracture management surgery. The secondary outcome will include unplanned 426 fracture-related reoperations that occur within one-year of their fracture. A blinded Adjudication 427
Committee will review SSIs and unplanned fracture-related reoperations to confirm that they 428 meet the criteria for being a study event. 
Pragmatic-Explanatory Continuum 433
In accordance with recommended methodology standards, we have used the PRagmatic-434
Explanatory Continuum Indicator Summary (PRECIS-2) toolkit to evaluate the PREPARE trial 435 design decisions to determine whether these decisions will lead to a study that answers, "Does 436 this intervention work under usual conditions?" (pragmatic) versus "Can this intervention work 437 under ideal conditions?" (explanatory). The PRECIS-2 tool uses a 5-point Likert scale in 9 438 domains to evaluate the continuum of design choices. A domain score of 5 indicates "very 439 pragmatic," while a score of 1 suggests "very explanatory." Table 1 outlines the investigators' 440 assessment of the trial design and the rationale for each assessed score and Figure 3 displays the 441 PRECIS-2 wheel. 442 443 Recruitment 5 Recruitment of all consenting fracture patients treated at each participating hospital will be performed.
Setting 4
Recruitment is occurring at multiple sites across the US and Canada; however, since most of the recruiting hospitals are regional referral centers the setting is "mostly pragmatic."
Organization 5
The interventions do not need an increase in providers or care delivery compared to the usual antiseptic care provided. For each antiseptic solution, a brief in-service training session will be provided to the clinical sites, as per any new product/procedure that is being introduced into an operating room.
Flexibility (delivery)
5 The interventions will be delivered in the usual care manner with no advice on allowed co-interventions or strict protocols to ensure compliance.
Flexibility (adherence) -
This section is left blank according to PRECIS-2 guidance because the intervention is provided prior to patient consent and individual patient compliance is not an issue. If provider adherence is considered, the study design is rather pragmatic (4) because there will be limited encouragement to follow the manufacturer's directions for use, other than periodic newsletters, investigator meetings, and possible provider survey during the recruitment period. Follow-up 5 All study follow-up is consistent with usual care.
Primary outcome 5
The outcome has been validated by patients as being very relevant to the study participants and it does not require specialized expertise beyond the treating physician for diagnosis.
Primary analysis 5 All available study data will be used for analysis following the intention to treat principle.
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Visits are to be completed at routine clinic visits. When necessary, visits may also be completed by telephone, text,
624
email, standard mail, and/or a review of the participant's medical record.
625
Follow-up visit windows touch so that participants will always fall into a specific window. The windows are: 4 to 8 626 weeks (i.e., 28 to 56 days), 2 to 4.5 months (i.e., 57 to 137 days), 4.5 to 7.5 months (i.e., 138 to 228 days), 7. possible that a recruiting cluster may achieve their overall enrollment goal sooner in one 667 population than the other. If this occurs, Methods Center personnel may instruct the recruiting 668 cluster to stop enrollment of the completed population and continue enrollment of only the other 669 fracture population. This decision will be made based on the overall study recruitment, 670 timelines, and other logistical concerns. 671 672
Randomization Methods

673
Treatment allocation will be determined using a cluster-randomized crossover trial design. The 674 order of treatment allocation for each orthopaedic practice (cluster) will be randomly assigned 675 using a computer-generated randomization table. Each site will start with the initially allocated 676 study solution and crossover to the other solution for their second recruitment period. Both the 677 open fracture and closed lower extremity and pelvic fracture populations will receive the same 678 treatment allocation and follow the same crossover schedule. The process of alternating 679 treatments will repeat approximately every two months as dictated by the initial randomization. 680
For sites that enroll for more than 1 year, the order of treatment allocation may be reversed after 681 12 months to ensure equal distribution of each treatment across each calendar month in the 682 study's duration (Figure 2 ). Randomization will be completed by personnel at the CEO Methods 683
Center at the onset of the trial. Personnel from the Methods Center will notify personnel at each 684 participating clinical site of their treatment allocation order. This will allow each participating 685 clinical site to begin preparing for the first run-in period. 686 687
Blinding 688
The orthopaedic team (including the study coordinators) cannot be blinded to the treatment 689 allocation as the antiseptic solutions are visually distinguishable and these individuals need to 690 lead the implementation of the cluster-crossover protocol at their clinical site. The Adjudication 691
Committee Members and data analysts will be blinded to the study treatment. All interpretations 692
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of study results will initially be done in a blinded manner by developing two interpretations of 693 the results. One interpretation will assume treatment A is iodine povacrylex (0.7% free iodine) in 694 74% isopropyl alcohol, the other interpretation will assume it is 2% CHG in 70% isopropyl 695 alcohol. Once the data interpretations for each assumption are finalized, the data will be 696 unblinded and the correct interpretation will be accepted. patients and 628 closed lower extremity and pelvic fracture patients), and it is anticipated that 732 most recruiting centers will exceed this minimum goal. Methods Center personnel will continue 733 to monitor compliance with the assigned pre-operative antiseptic skin solution over the 734 enrollment phase and work collaboratively with the clinical sites to minimize cases in which a 735 patient receives the incorrect solution. These monitoring activities will coincide with site-specific 736 procedures to maintain compliance for all patients, even those requiring multiple surgical 737
procedures. All assessments of compliance will be analyzed separately for the open and closed 738 fracture populations. If a fracture requires multiple surgeries and the correct solution is not 739 Version: 2.1 04-Nov-2019 applied at each procedure, the patient will remain in the study and be analyzed using the 740 allocated solution (ITT principle). 741 742 4.6.3 Second Intervention Phase 743
Once the first intervention phase is completed, each site will crossover to the opposite study 744 solution. This crossover will occur simultaneously in the open and closed fracture populations. 745
There will be no run-in phase for the second solution and each site will need to develop local 746 procedures to ensure a successful crossover. Example procedures to minimize carry-forward of 747 first solution into the second solution phase include: 1) removing the bottles of the first solution 748 from the orthopaedic operating rooms; 2) changing study posters and notifications within the 749 operating rooms; and 3) performing the crossover during the middle of the week to provide a few 750 days' notice to the operating room staff and to avoid contamination of recent fracture patients 751 returning for repeat procedures (e.g., weekend admissions). The enrollment goals and procedures 752 will mirror the first intervention phase. Methods Center personnel will continue to monitor 753 compliance with the assigned pre-operative antiseptic skin solution over the enrollment phase 754 and work collaboratively with the clinical sites to reduce the risk of contamination. 755 756 4.6.4 Special Considerations for Ongoing Treatment Crossovers 757 Treatment allocation will continue to alternate between the study solutions, as outlined above, 758
for the remainder of study duration. Each intervention phase will be approximately two months 759 in duration, as agreed upon by the clinical site and CEO Methods Center personnel. The duration 760 may be modified to avoid crossovers on holidays, weekends, and other circumstances that could 761 threaten a successful crossover. The expected recruitment duration for the trial is approximately 762 24 months; however, some sites may have a shorter total recruitment duration (e.g., a 763 participating site that joins the trial later, high volume clinical sites, etc.). The two-month 764 enrollment periods will help account for seasonal variability in SSI incidence and their 765 associated infectious organisms, 36 as each crossover period will cover a season. In addition, for 766 those clinical sites enrolling beyond 12 months, the distribution of recruitment periods for each 767 solution may be seasonally matched by reversing the order of the alternating allocation after 12 768 months of recruitment. 769 770 4.6.5 Evaluation of Site Performance and Removal of Clinical Sites 771
After every two recruitment periods (approximately every four months), each site will be 772 evaluated for continued participation in the trial. Sites with <90% of eligible patients receiving 773 the allocated solution, differential adherence between study solutions, <95% follow-up of the 774 primary outcome, <90% follow-up of the secondary outcome, incomplete data submission, or 775 other threats to data quality or the validity of the study may be withdrawn from the trial. In the 776 event a site is withdrawn, data collection will be completed for all enrolled participants and these 777 data will be included in the final study analysis. 778 779 4.6.6 Application of Pre-Operative Antiseptic Skin Solutions 780 Each solution will be applied to the skin and allowed to dry for a minimum of three minutes. 781
While the application and minimum drying time for both study solutions are very similar, local 782 study personnel will provide standardized in-service (training) for orthopaedic surgeons, 783 operating room technicians, and nurses at each participating hospital prior to the initial run-in 784 phase. This training should include reviewing the manufacturers' directions for use to help 785 minimize incorrect application at clinical sites that may not routinely use both solutions. In 786
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The study protocol will mandate the antiseptic skin solution to be used in each intervention phase 790 (Sections 4.4, 4.6.1, 4.6.2, 4.6.3, and 4.6.4); however, the protocol will remain pragmatic to 791 variability in the actual application of the solutions and other co-intervention steps performed 792 during the entire pre-operative skin preparation process performed in the operating room. Based 793 on individual surgeon preference, this often includes mechanically removing visible dirt or 794 debris with a scrub brush, and/or cleaning the limb with isopropyl alcohol or an antiseptic scrub 795 solution. These additional skin preparation steps will be permitted provided that: 1) the final skin 796 preparation step prior to surgical incision is the application of the allocated antiseptic solution; 797 and, 2) participating surgeons continue to use the same skin preparation co-interventions in both 798 intervention phases. Co-interventions that contain the opposite active ingredient from the current 799 intervention phase (e.g., using a CHG scrub brush during the iodine intervention phase, or 800 conversely, using an iodine scrub during the CHG intervention phase) should be avoided; 801 however, deviations from this recommendation will be permitted to maintain pragmatic 802 flexibility of delivery and reflect real-world clinical practice. This is the primary rationale for the cluster-crossover design, in which each participating hospital 846 will act as its own control for the effect of co-interventions. Therefore, four key approaches to 847 account for and limit the potential differential application of co-interventions during the study 848 periods will be performed: 1) study periods for each intervention are kept relatively short to 849 improve the likelihood that newly implemented co-interventions will be equally distributed 850 across both treatment solutions; 2) encourage participating hospitals not to make changes to their 851 existing infection prevention interventions during the study periods; 3) document the co-852 interventions being used in the hospitals throughout the study periods; and 4) record any changes 853 in co-interventions that do occur if mandated by a participating hospital's administration. 
875
The CDC criteria for classifying SSIs will be followed. If multiple tissue levels are involved in 876 the infection, the type of SSI (superficial incisional, deep incisional, or organ/space) reported 877 will reflect the deepest tissue layer involved in the infection during the surveillance period. The 878 date of event will be the date that the participant met criteria for the deepest level of infection 879 using the following procedures: 1) report infection that involves the organ/space as an 880 organ/space SSI, whether or not it also involves the superficial or deep incision sites and 2) 881 report infection that involves the superficial and deep incisional sites as a deep incisional SSI.
882
The most relevant National Healthcare Safety Network Organ/Space SSI classifications are 883 summarized in Table 4 . Whenever possible, the treating surgeon or study personnel should take 884 photos of the infected region to facilitate the adjudication process. 885 886 The secondary outcome is unplanned fracture-related reoperation within 12 months of the 900 fracture(s). This outcome has been used in previous fracture trials and is defined as any 901 unplanned surgery that occurred from the time of injury to 12 months post-injury that is 902 associated with an infection at the operative site or contiguous to it, a wound-healing problem, or 903 a fracture delayed union or nonunion. The second exploratory outcome is SSI using the CDC criteria within 12 months of the fracture.
940
This secondary outcome will use the same diagnostic CDC reporting criteria for the primary 941 outcome (Tables 3 and 4) ; however, the timeframe for this outcome will be expanded to include 942 all SSIs that occur within 12 months of fracture. Similar to the rationale for using the FRI 943 outcome, and the recommendations for a minimum of 12 months follow-up for orthopaedic 944 fracture outcomes 40 , this expanded timeframe will detect infections that occur beyond the 945 standard CDC surveillance reporting periods. This modification of the CDC reporting periods 946 has been used in previous orthopaedic fracture trials. After obtaining informed consent, study personnel will record the baseline data on the study 954 CRFs. They will obtain this information directly from the participant or proxy, from the 955 participant's medical chart, and the participant's treating orthopaedic surgeon or other health 956 care providers. Data collection points include participant characteristics and injury details such 957 as age, gender, comorbidities, mechanism of injury, and other injuries. Study personnel will also 958 record the characteristics of up to three eligible fracture regions including the bone(s) fractured, 959 fracture severity, size of the wound (if applicable), and degree of soft tissue injury using the 960 Tscherne classification in closed fractures and the Gustilo classification in open fractures. 1, 34, 36 961 962 Surgical data and in-hospital data will be collected throughout the participant's hospital stay. 963
Detailed information will be collected regarding the surgical management of their fracture(s), 
